- Home
- PRCH vs MLTX Comparison
PRCH vs MLTX Comparison
Compare PRCH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCH | MLTX |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRCH | MLTX |
|---|---|---|
| Price | $16.73 | $14.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $18.63 | ★ $27.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | N/A |
| P/E Ratio | $1,794.00 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $6.36 | $5.95 |
| 52 Week High | $19.44 | $62.75 |
Technical Indicators
Market Signals| Indicator | PRCH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 34.25 |
| Support Level | $9.15 | $14.55 |
| Resistance Level | $17.03 | $15.48 |
| Average True Range (ATR) | 0.70 | 0.58 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 12.96 | 14.38 |
Price Performance
Historical ComparisonAbout PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.